I
Ioline D. Henter
Researcher at National Institutes of Health
Publications - 77
Citations - 4235
Ioline D. Henter is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Bipolar disorder & Major depressive disorder. The author has an hindex of 31, co-authored 69 publications receiving 3291 citations. Previous affiliations of Ioline D. Henter include Government of the United States of America & Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
Nancy Diazgranados,Lobna Ibrahim,Nancy E. Brutsche,Rezvan Ameli,Ioline D. Henter,David A. Luckenbaugh,Rodrigo Machado-Vieira,Carlos A. Zarate +7 more
TL;DR: Suicidal ideation in the context of MDD improved within 40 minutes of a ketamine infusion and remained improved for up to 4 hours postinfusion.
Journal ArticleDOI
Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study
Lobna Ibrahim,Nancy Diazgranados,Nancy Diazgranados,Jose A. Franco-Chaves,Nancy E. Brutsche,Ioline D. Henter,Phillip Kronstein,Phillip Kronstein,Ruin Moaddel,Irving W. Wainer,David A. Luckenbaugh,Husseini K. Manji,Carlos A. Zarate +12 more
TL;DR: The effect size of improvement with ketamine was initially large and remained moderate throughout the 28-day trial, suggesting that the combination of riluzole with ketamines treatment did not significantly alter the course of antidepressant response to ketamine alone.
Journal ArticleDOI
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Carlos A. Zarate,Rodrigo Machado-Vieira,Ioline D. Henter,Lobna Ibrahim,Nancy Diazgranados,Giacomo Salvadore +5 more
TL;DR: Evidence confirming the role of the glutamatergic modulators riluzole and ketamine as proof-of-concept agents in this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder.
Journal ArticleDOI
The neurobiology of the switch process in bipolar disorder: a review.
Giacomo Salvadore,Jorge A. Quiroz,Rodrigo Machado-Vieira,Ioline D. Henter,Husseini K. Manji,Carlos A. Zarate +5 more
TL;DR: In this article, the authors summarize the clinical evidence regarding somatic interventions associated with switching, with a particular focus on the biological underpinnings presumably involved in the switch process.
Journal ArticleDOI
Targeting the Glutamatergic System to Treat Major Depressive Disorder
TL;DR: Evidence that the glutamatergic system holds considerable promise for developing the next generation of novel and mechanistically distinct agents for the treatment of MDD is reviewed, particularly with regard to the N-methyl-D-aspartate (NMDA) antagonist ketamine as a ‘proof-of-concept’ agent.